Quick Answer
Xenetic Biosciences, Inc. reported Stockholders Equity of $7.40 million for fiscal year 2025.
Xenetic Biosciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $7.40M | +23.1% |
| 2024 | $6.01M | -38.7% |
| 2023 | $9.80M | -28.2% |
| 2022 | $13.65M | -25.8% |
| 2021 | $18.39M | +50.6% |
| 2020 | $12.22M | -29.0% |
| 2019 | $17.21M | +73.6% |
| 2018 | $9.91M | -30.7% |
| 2017 | $14.30M | -11.6% |
| 2016 | $16.17M | +144.7% |
| 2015 | $6.61M | -36.9% |
| 2014 | $10.48M | -16.9% |
| 2013 | $12.62M | +7029.8% |
| 2013 | -$182.1K | -100.9% |
| 2012 | $20.78M | +22464.8% |
| 2012 | -$92.9K | +0.0% |
| 2011 | -$92.9K | -5363.9% |
| 2011 | $1.8K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.96M | -43.8% | -11.1% |
| June 30, 2025 | $4.45M | -40.2% | -13.1% |
| March 31, 2025 | $5.12M | -41.0% | -14.7% |
| December 31, 2024 | $6.01M | -38.7% | -14.6% |
| September 30, 2024 | $7.04M | -35.4% | -5.5% |
| June 30, 2024 | $7.45M | -37.3% | -14.2% |
| March 31, 2024 | $8.68M | -32.5% | -11.4% |
| December 31, 2023 | $9.80M | -28.2% | -10.1% |
- Xenetic Biosciences, Inc. showed an increase of +23.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Xenetic Biosciences, Inc.’s stockholders equity has grown by 418926.7% (from $1.8 thousand to $7.40 million).
- The most recent figure is from Xenetic Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: